BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21637785)

  • 1. Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts.
    Hennessey PT; Ochs MF; Mydlarz WW; Hsueh W; Cope L; Yu W; Califano JA
    PLoS One; 2011; 6(5):e20584. PubMed ID: 21637785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma.
    Pattani KM; Soudry E; Glazer CA; Ochs MF; Wang H; Schussel J; Sun W; Hennessey P; Mydlarz W; Loyo M; Demokan S; Smith IM; Califano JA
    PLoS One; 2012; 7(9):e45534. PubMed ID: 23029077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
    Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
    Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.
    Demokan S; Chuang AY; Pattani KM; Sidransky D; Koch W; Califano JA
    Oncol Rep; 2014 Feb; 31(2):1014-20. PubMed ID: 24337411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene promoter-associated CpG island hypermethylation in squamous cell carcinoma of the tongue.
    Bhat S; Kabekkodu SP; Jayaprakash C; Radhakrishnan R; Ray S; Satyamoorthy K
    Virchows Arch; 2017 Apr; 470(4):445-454. PubMed ID: 28255813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications.
    Maruya S; Issa JP; Weber RS; Rosenthal DI; Haviland JC; Lotan R; El-Naggar AK
    Clin Cancer Res; 2004 Jun; 10(11):3825-30. PubMed ID: 15173091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
    Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
    Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aberrant promoter hypermethylation of tazarotine-induced gene 1 (TIG1) in head and neck cancer].
    Tokumaru Y; Yahata Y; Fujii M
    Nihon Jibiinkoka Gakkai Kaiho; 2005 Dec; 108(12):1152-7. PubMed ID: 16440812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
    Schmitt K; Molfenter B; Laureano NK; Tawk B; Bieg M; Hostench XP; Weichenhan D; Ullrich ND; Shang V; Richter D; Stögbauer F; Schroeder L; de Bem Prunes B; Visioli F; Rados PV; Jou A; Plath M; Federspil PA; Thierauf J; Döscher J; Weissinger SE; Hoffmann TK; Wagner S; Wittekindt C; Ishaque N; Eils R; Klussmann JP; Holzinger D; Plass C; Abdollahi A; Freier K; Weichert W; Zaoui K; Hess J
    Int J Cancer; 2019 Dec; 145(12):3299-3310. PubMed ID: 31135957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.
    Chen X; Liu L; Mims J; Punska EC; Williams KE; Zhao W; Arcaro KF; Tsang AW; Zhou X; Furdui CM
    Epigenetics; 2015; 10(6):545-61. PubMed ID: 25961636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
    Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
    Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the methylation of Wnt pathway antagonists-CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling-ZIC1, ZIC4, and HHIP in head and neck squamous cell carcinomas.
    Paluszczak J; Wiśniewska D; Kostrzewska-Poczekaj M; Kiwerska K; Grénman R; Mielcarek-Kuchta D; Jarmuż-Szymczak M
    Clin Oral Investig; 2017 Jun; 21(5):1777-1788. PubMed ID: 27553089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.
    Guerrero-Preston R; Michailidi C; Marchionni L; Pickering CR; Frederick MJ; Myers JN; Yegnasubramanian S; Hadar T; Noordhuis MG; Zizkova V; Fertig E; Agrawal N; Westra W; Koch W; Califano J; Velculescu VE; Sidransky D
    Epigenetics; 2014 Jul; 9(7):1031-46. PubMed ID: 24786473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.
    Poage GM; Christensen BC; Houseman EA; McClean MD; Wiencke JK; Posner MR; Clark JR; Nelson HH; Marsit CJ; Kelsey KT
    PLoS One; 2010 Mar; 5(3):e9651. PubMed ID: 20300172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.
    Steinmann K; Sandner A; Schagdarsurengin U; Dammann RH
    Oncol Rep; 2009 Dec; 22(6):1519-26. PubMed ID: 19885608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC).
    Smiraglia DJ; Smith LT; Lang JC; Rush LJ; Dai Z; Schuller DE; Plass C
    J Med Genet; 2003 Jan; 40(1):25-33. PubMed ID: 12525538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inactivation of RASSF1A in head and neck cancer.
    Dong SM; Sun DI; Benoit NE; Kuzmin I; Lerman MI; Sidransky D
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3635-40. PubMed ID: 14506151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter methylation in head and neck tumorigenesis.
    Stephen JK; Chen KM; Havard S; Harris G; Worsham MJ
    Methods Mol Biol; 2012; 863():187-206. PubMed ID: 22359294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer.
    Worsham MJ; Chen KM; Stephen JK; Havard S; Benninger MS
    Otolaryngol Head Neck Surg; 2010 Jul; 143(1):116-21, 121.e1-19. PubMed ID: 20620629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.